Olanzapine News and Research

RSS

Olanzapine (trade names Zyprexa, Zyprexa Zydis, Zalasta, Zolafren, Olzapin, Rexapin or in combination with fluoxetine Symbyax) is an atypical antipsychotic, approved by the FDA for the treatment of schizophrenia and bipolar disorder.

Hyponatremia risk varies among individual second-generation antipsychotic drugs

Antipsychotics are used to treat schizophrenia, along with bipolar disorder and major depressive disorder. However, these medications can be associated with hyponatremia, a serious reduction in blood sodium levels.

8 Oct 2026

Semaglutide outperforms other GLP-1 drugs for weight loss in psychiatric populations

A network meta-analysis of nine randomized controlled trials found that once-weekly semaglutide showed the largest estimated weight-loss effect among GLP-1 receptor agonists tested in adults with mental illness and obesity or related metabolic risk. The authors cautioned that the findings remain preliminary because the evidence base was small, heterogeneous, and largely indirect.

9 Jul 2026

Trazodone linked to safer delirium outcomes in older adults

A large U.S. study suggests that older adults hospitalized with delirium may experience better outcomes when treated with trazodone, commonly used to treat depression and sleep problems, rather than commonly used antipsychotic medications.

3 Feb 2026

Low-dose olanzapine reduces chemo-induced nausea with fewer side effects

Chemotherapy-induced nausea and vomiting are among the most distressing side effects of anti-cancer treatment, particularly for those receiving highly emetogenic regimens such as anthracycline plus cyclophosphamide combinations.

24 Jul 2025

The brain-gut microbiota axis: Impact on mental health & potential treatment avenues

To be decided by the editor

From Atlantia Clinical Trials 28 Feb 2025

Risks of antipsychotic use in dementia extend beyond previous alerts, study shows

Antipsychotic use in people with dementia is associated with higher risks of a wide range of serious health outcomes compared with non-use, according to a new study from a collaboration across the Universities of Manchester, Nottingham, Edinburgh and Dundee.

23 Apr 2024

Study shows antipsychotic drugs increase health risks in dementia patients

Study found that antipsychotic drug use in dementia patients is linked to increased risks of stroke, heart failure, and other serious conditions.

18 Apr 2024

Antipsychotics for dementia associated with elevated risks of serious adverse outcomes

Antipsychotic use in people with dementia is associated with elevated risks of a wide range of serious adverse outcomes including stroke, blood clots, heart attack, heart failure, fracture, pneumonia, and acute kidney injury, compared with non-use, finds a study published by The BMJ today.

17 Apr 2024

Pharmacogenomics holds promise for personalized dementia therapies

Pharmacogenomics-based studies in the research for personalized therapeutics for dementia

8 Nov 2023

The association between breastfeeding, drug exposure, and infant outcomes: more research is needed

Researchers explored the data linking breastfeeding, infant outcomes, and drug exposure.

28 Apr 2023

New insight into the possible ASD-cardiometabolic diseases link

A study conducted by the Centers for Disease Control and Prevention (CDC) from 2009 to 2017 determined that approximately 1 in 44 children ages 3-17 are diagnosed with some form of autism spectrum disorder (ASD).

10 Mar 2023

Medical cannabis use reduces sleep disturbances caused by PTSD

Researchers assess the association between the use of medical cannabis and sleep.

21 Sep 2022

Temporo-spatial pharmacometabolomics method to evaluate microregional effect of OLZ on brain tissue

Announcing a new article publication from Acta Pharmaceutica Sinica B. The brain is the most advanced organ with various complex structural and functional microregions.

5 Sep 2022

Antipsychotic drugs associated with increase in risk of breast cancer

Researchers at Washington University School of Medicine in St. Louis have found that many commonly prescribed antipsychotic medications are associated with a significant increase in risk of breast cancer.

6 Dec 2021

Medications commonly prescribed for schizophrenia linked to cognitive impairment

Writing in the May 14, 2021 issue of The American Journal of Psychiatry, a multi-institution team of scientists led by researchers at University of California San Diego School of Medicine report that medications commonly prescribed to reduce the severity of physical and mental health symptoms associated with schizophrenia may have a cumulative effect of worsening cognitive function in patients.

18 May 2021

Study explains why antipsychotic medications lead to weight gain, promote metabolic syndrome

Why do patients who receive antipsychotic medications to manage schizophrenia and bipolar disorder quickly gain weight and develop prediabetes and hyperinsulemia?

15 Feb 2021

Olanzapine drug can help manage nausea and vomiting in patients with advanced cancer

Olanzapine, a generic drug used to treat nervous, emotional and mental conditions, also may help patients with advanced cancer successfully manage nausea and vomiting unrelated to chemotherapy.

8 May 2020

How cannabis interacts with medications

A new practice guideline published in the journal CMAJ in February 2020 describes five types of drug interactions possible with the use of cannabis. Cannabis is a plant-derived drug containing the psychoactive ingredient delta-9-tetrahydrocannabinol (THC) and non-psychoactive cannabidiol (CBD). These cannabinoids are broken down by the liver enzymes cytochrome P450 C(YP)34A, and CYP2CC9.

2 Mar 2020

Protein SV2A levels could explain poor neuronal connections in schizophrenia

A team of researchers have found that persons with schizophrenia may have lower levels of certain specific proteins that show up on their brain scans. This could help as diagnostic tools, say experts. The new study titled, “Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats”, is published in the latest issue of the journal Nature Communications.

14 Jan 2020

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018